Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Targeting High Fatality Cancers - Innovation Grant

McGill University

$99,997.00

Generation of a new therapeutic approach against advanced pancreatic cancer by modulating protein tyrosine phosphatases

EF 2015-16

Résumé
Anti-cancer therapies have multiplied in recent years, notably because of technological and scientific progress in the field of personalized medicine where targeted therapies are being selected based on the genetic profiles of both tumours and patients. Additionally, because of recent advances in tumour immunology, important developments have occurred in the field of immunotherapies. These new therapeutic approaches bring great promise for novel cancer treatments that could tackle all types of human cancers. The scientific basis for these therapeutic regimens is to reactivate or boost patients' own immune systems in order to promote the recognition and killing of their tumour cells. This proposal is centred on a novel discovery by our laboratory that identified specific enzymes named PTPs as repressor of dendritic cell, the main orchestrator of anti-cancer immune response. We plan to further characterize the regulatory role of PTPs in dendritic cells and test the efficacy of inhibiting PTPs in order to potentiate dendritic cell-based therapies. We have successfully performed some of these studies in mice and in dendritic cells (DCs) from pancreatic cancer patients, which resulted in the prevention of tumour growth and significantly enhanced DC functions respectively. This research provides a valuable framework for the generation of new DC-based immunotherapy for pancreatic cancer.
Programme
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
341726
Name
Tremblay Michel L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Targeting High Fatality Cancers Innovation Grant
Projecttitle
Generation of a new therapeutic approach against advanced pancreatic cancer by modulating protein tyrosine phosphatases
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$99,997
Cihrequipment2
$0
Programname2
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Keyworddelim
Antigen Presentation; Cell-Based Therapy; Costimulatory Molecules; Cytotoxic T Cells; Dendritic Cells; Lymphomas; Pancreatic Cancer; Proinflammatory Cytokines; Protein Tyrosine Phosphatases; Vaccine
Abstract
Anti-cancer therapies have multiplied in recent years, notably because of technological and scientific progress in the field of personalized medicine where targeted therapies are being selected based on the genetic profiles of both tumours and patients. Additionally, because of recent advances in tumour immunology, important developments have occurred in the field of immunotherapies. These new therapeutic approaches bring great promise for novel cancer treatments that could tackle all types of human cancers. The scientific basis for these therapeutic regimens is to reactivate or boost patients' own immune systems in order to promote the recognition and killing of their tumour cells. This proposal is centred on a novel discovery by our laboratory that identified specific enzymes named PTPs as repressor of dendritic cell, the main orchestrator of anti-cancer immune response. We plan to further characterize the regulatory role of PTPs in dendritic cells and test the efficacy of inhibiting PTPs in order to potentiate dendritic cell-based therapies. We have successfully performed some of these studies in mice and in dendritic cells (DCs) from pancreatic cancer patients, which resulted in the prevention of tumour growth and significantly enhanced DC functions respectively. This research provides a valuable framework for the generation of new DC-based immunotherapy for pancreatic cancer.
Competitiondate
201601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremblay, Michel L
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $99,997~ $0~